DOCSLIB.ORG

Activities of Nicotinic Acetylcholine Receptors Modulate Neurotransmission and Synaptic Architecture

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

NEURAL REGENERATION RESEARCH December 2014,Volume 9,Issue 24 www.nrronline.org INVITED REVIEW Activities of nicotinic acetylcholine receptors modulate neurotransmission and synaptic architecture Akira Oda1, Hidekazu Tanaka2 1 CNS Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 2-26-1, Muraoka-higashi, Fujisawa, Kanagawa 251-8555, Japan 2 Laboratory of Pharmacology, Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, 1-1-1, Noji-higashi, Kusatsu, Shiga 525-8577, Japan Abstract Corresponding author: The cholinergic system is involved in a broad spectrum of brain function, and its failure has Hidekazu Tanaka, M.D., Ph.D., been implicated in Alzheimer’s disease. Acetylcholine transduces signals through muscarinic Laboratory of Pharmacology, Department and nicotinic acetylcholine receptors, both of which influence synaptic plasticity and cognition. of Biomedical Sciences, College of Life However, the mechanisms that relate the rapid gating of nicotinic acetylcholine receptors to per- Sciences, Ritsumeikan University, sistent changes in brain function have remained elusive. Recent evidence indicates that nicotinic [email protected]. acetylcholine receptors activities affect synaptic morphology and density, which result in per- sistent rearrangements of neural connectivity. Further investigations of the relationships between doi:10.4103/1673-5374.147943 nicotinic acetylcholine receptors and rearrangements of neural circuitry in the central nervous http://www.nrronline.org/ system may help understand the pathogenesis of Alzheimer’s disease. Accepted: 2014-11-03 Key Words: cholinergic system; nicotinic acetylcholine receptors (nAChRs); Alzheimer’s disease (AD); synaptic transmission; synaptic plasticity; synaptic morphology; dendritic spine remodeling; cognition Funding: Tanaka H is supported by the Takeda Science Foundation and JSPS KAKENHI Grant Number 19590247. Oda A, Tanaka H. Activities of nicotinic acetylcholine receptors modulate neurotransmission and synaptic architecture. Neural Regen Res. 2014;9(24):2128-2131. Nicotinic receptors in the central nervous junctive use of acetylcholinesterase inhibitors alleviates visual hallucinations (Patel et al., 2010). In contrast, acetylcholine system (CNS) are candidate targets for the receptor antagonism ameliorates depressive symptoms in ma- treatment of dementia jor depression and bipolar disorders (Drevets et al., 2013). Dementia is one of the biggest global public health challeng- The neurotransmitter acetylcholine transduces signals es. Accordingly, over 40 million people suffer from dementia through muscarinic and nicotinic acetylcholine receptors. globally, and this number is expected to double by 2030 and Nicotinic acetylcholine receptor (nAChR) comprises five more than triple by 2050 (Alzheimer’s disease International, subunit polypeptides. Brain-type nAChRs consist of hetero- World Alzheimer Report 2014). Alzheimer’s disease (AD) meric combinations of α2–10 and β2–4 subunits, as well as α7 * is the most common type of dementia, and accounts for an homopentamers; α4β2 and α7 nAChRs are predominantly estimated 60 to 80% of cases. expressed in the brain (an asterisk indicates that the receptor Loss of cholinergic neurons is a pathological hallmark of may include other subunits than the described ones). In the AD, and is also assessed in human imaging studies (Nordberg pathophysiology of AD, amyloid β (Aβ), the peptide in senile et al., 2010). Cholinergic neurons of the nucleus basalis of plaques characteristic of AD, binds with high affinity to α7 Meynert and the medial septum innervate the cerebral cortex nAChRs, and impairs their channel functions. The selective and the hippocampus, respectively, and are involved in cog- vulnerability of nAChR-expressing neurons to Aβ toxicity nition. Hence enhancement of cholinergic transmission with may lead to the failure of cholinergic neurotransmission and acetylcholinesterase inhibitors ameliorates cognitive deficits cognitive dysfunctions in AD (Dineley, 2007). in AD patients (Rogers et al., 1998). Consistently, deprivation Several nAChR-targeting compounds have been developed of cholinergic transmission by either genetic disruption of to relieve neuropsychiatric symptoms in AD patients. However, * acetylcholine receptors or denervation of cholinergic nerve clinical trials of compounds that target α4β2 and α7 nAChRs fibers severely impairs learning and memory in animal exper- (Table 1) have produced discouraging results (see review, iments (Champtiaux and Changeux, 2004; Wess, 2004). Hurst et al., 2013). For example, varenicline, a partial agonist * The cholinergic system also plays pivotal roles in other of α4β2 nAChR, is the only clinically available nAChR-target- psychiatric disorders (Scarr et al., 2013). For example, an ing drug, and was approved for smoking cessation, but failed imbalance between cholinergic and dopaminergic systems to improve cognition in AD patients (Kim et al., 2014). contributes to the pathophysiology of schizophrenia, and ad- The failure of nAChR-targeting therapy for AD may be at- 2128 Oda A, et al. / Neural Regeneration Research. 2014;9(24):2128-2131. Table 1 Development of nicotinic acetylcholine receptor (nAChR) ligands for the treatment of Alzheimer’s disease and cognitive disorders Molecular Development Code name Generic name Company mechanism Indication status Notes EVP-6124, Encenicline FORUM α7 nAChR Alzheimer's disease Phase 3 A phase 3 program called cognitive MT-4666 hydrochloride Pharmaceuticals agonist Alzheimer's disease is set to run through 2016. ABT-126 AbbVie α7 nAChR Alzheimer's disease Phase 2 ABT-126 is also in phase 3 development agonist for cognitive impairment associated with schizophrenia. AZD-3480, Ispronicline Targacept α7 nAChR Alzheimer's disease Phase 2 Phase 2b clinical trial in Alzheimer’s disease TC-1734 agonist does not show superiority of TC-1734 over donepezil in July, 2014. DMXBA, DMXB- CoMentis α7 nAChR Alzheimer's disease Phase 2 GTS-21 anabaseine partial agonist AQW051 Novartis α7 nAChR Cognitive impairment Phase 2 Phase 2 trial in mild Alzheimer's disease was partial agonist associated with discontinued. schizophrenia ABT-560, Abbott, α4β2 nAChR Cognitive disorders Phase 1 ABT-PR2 NeuroSearch agonist CP-526555- Varenicline Pfizer α4β2 partial Alzheimer's disease Discontinued Development of varenicline for Alzheimer's 18 tartrate nAChR therapy was discontinued in 2011, based on agonist negative results from phase 2 trial conducted in South Korea. TC-5619 Bradanicline Targacept α7 nAChR Alzheimer's disease Discontinued In 2013, Targacept announced negative agonist results for phase 2b clinical trials of schizophrenia, and decided not to pursue further development for the treatment of either schizophrenia or Alzheimer’s disease. MEM 3454, Facinicline Roche α7 nAChR Alzheimer's disease Discontinued R3487, hydrochloride partial agonist RG3487, 5-HT3 RO5313534 antagonist SSR 180711 Sanofi α7 nAChR Alzheimer's disease Discontinued partial agonist AZD-1446, AstraZeneca α4β2 nAChR Alzheimer's disease Discontinued TC-6683 agonist A-87089, Pozanicline Abbott nAChR partial Alzheimer's disease Discontinued ABT-089 hydrochloride agonist A-81418, Abbott nAChR Alzheimer's disease Discontinued ABT-418 agonist ABT-107, Abbott, α7 nAChR Cognitive disorders Discontinued In 2009, development of ABT-107 was ABT-PR1 NeuroSearch agonist discontinued in phase 1 trials. AR- AstraZeneca α7 nAChR Alzheimer's disease Discontinued In 2009, AstraZeneca discontinued the R23465XX, agonist development of AZD-0328 as a potential AZD-0328 treatment option for Alzheimer’s disease in phase 2 trials in Europe. Drug information was sourced from Alzforum, the Schizophrenia Research Forum, and a recent review article (Hurst et al., 2013). This source was amended upon availability of more accurate information on company websites. 5-HT3: 5-Hydroxytryptamine 3. tributed to several reasons. First, the expression of nAChRs Third, adverse effects of nAChR-targeting compounds, such is down-regulated in the brains of AD patients (Nordberg as gastrointestinal and CNS-related side effects (Hurst et al., * et al., 2010). Moreover, the expression of α4β2 nAChRs 2013), may limit therapeutic doses of compounds. To cir- is decreased in these patients, especially in affected brain cumvent these side effects, partial agonists for nAChRs have areas, and appears to be correlated with the severity of cog- been developed with the expectation of broader therapeutic nitive impairment and the amount of amyloid deposition windows than full agonists (Table 1). Nonetheless, a better (Sabri et al., 2008; Okada et al., 2013). Conditions relating understanding of the relationships between nAChRs and to α7 nAChRs have been more controversial, with reports plasticity or rearrangements of neural circuitry may be re- of decreased (Burghaus et al., 2000), stable (Ikonomovic et quired for the successful treatment of AD. al., 2009), and increased (Nordberg, 2001) α7 nAChR ex- pression in AD patients. Second, tested compounds have insufficient potencies, and under conditions of decreased Nicotinic activity modulates plasticity and nAChR subunit expression, these reportedly activate only a various synaptic transmissions small fraction (about 10%) of nAChRs (Kim et al., 2014). In addition to acetylcholine, major neurotransmitters in 2129 Oda A, et al. / Neural Regeneration Research. 2014;9(24):2128-2131. Table 2 Nicotinic acetylcholine receptors modulate synaptic
Recommended publications
  • Role of Prefrontal Cortex and Cholinergic Modulation in Attentional

    Role of Prefrontal Cortex and Cholinergic Modulation in Attentional

    Role of prefrontal cortex and cholinergic modulation in attentional performance in rats Beth Mary Fisher Department of Psychology Downing College University of Cambridge September 2017 This dissertation is submitted for the degree of Doctor of Philosophy Declaration This dissertation is the result of my own work and includes nothing which is the outcome of work done in collaboration except as declared in the Preface and specified in the text. It is not substantially the same as any that I have submitted, or, is being concurrently submitted for a degree or diploma or other qualification at the University of Cambridge or any other University or similar institution except as declared in the Preface and specified in the text. I further state that no substantial part of my dissertation has already been submitted, or, is being concurrently submitted for any such degree, diploma or other qualification at the University of Cambridge or any other University or similar institution except as declared in the Preface and specified in the text. It does not exceed the prescribed word limit of the degree committee for the faculty of biology of 60,000 words. i2 Acknowledgements Firstly, I would like to thank my supervisor Tim Bussey and advisor Trevor Robbins for their invaluable support, guidance and encouragement throughout my PhD. Their insightful scientific discussions, passion for the field and praise of me, have shaped me to become a scientist I am proud of, and given me an unknown confidence. Not only are they experts in the field, but they are down to earth, kind and fun.
  • Nicotinic Receptors in Neurodegeneration

    Nicotinic Receptors in Neurodegeneration

    Send Orders of Reprints at [email protected] 298 Current Neuropharmacology, 2013, 11, 298-314 Nicotinic Receptors in Neurodegeneration Inmaculada Posadas, Beatriz López-Hernández and Valentín Ceña* Unidad Asociada Neurodeath. CSIC-Universidad de Castilla-La Mancha, Departamento de Ciencias Médicas. Albacete, Spain and CIBERNED, Instituto de Salud Carlos III, Spain Abstract: Many studies have focused on expanding our knowledge of the structure and diversity of peripheral and central nicotinic receptors. Nicotinic acetylcholine receptors (nAChRs) are members of the Cys-loop superfamily of pentameric ligand-gated ion channels, which include GABA (A and C), serotonin, and glycine receptors. Currently, 9 alpha (2-10) and 3 beta (2-4) subunits have been identified in the central nervous system (CNS), and these subunits assemble to form a variety of functional nAChRs. The pentameric combination of several alpha and beta subunits leads to a great number of nicotinic receptors that vary in their properties, including their sensitivity to nicotine, permeability to calcium and propensity to desensitize. In the CNS, nAChRs play crucial roles in modulating presynaptic, postsynaptic, and extrasynaptic signaling, and have been found to be involved in a complex range of CNS disorders including Alzheimer’s disease (AD), Parkinson’s disease (PD), schizophrenia, Tourette´s syndrome, anxiety, depression and epilepsy. Therefore, there is growing interest in the development of drugs that modulate nAChR functions with optimal benefits and minimal adverse effects. The present review describes the main characteristics of nAChRs in the CNS and focuses on the various compounds that have been tested and are currently in phase I and phase II trials for the treatment of neurodegenerative diseases including PD, AD and age-associated memory and mild cognitive impairment.
  • (19) United States (12) Patent Application Publication (10) Pub

    (19) United States (12) Patent Application Publication (10) Pub

    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
  • Evidence of Efficacy for TC-1734 (AZD3480) in the Treatment of Cognitive Impairment in Older Subjects Geoffrey C

    Evidence of Efficacy for TC-1734 (AZD3480) in the Treatment of Cognitive Impairment in Older Subjects Geoffrey C

    Evidence of Efficacy for TC-1734 (AZD3480) in the Treatment of Cognitive Impairment in Older Subjects Geoffrey C. Dunbar, Iphigenia L. Koumenis, Ramana V. Kuchibhatla, James K. Wamsley Targacept, Inc., Winston-Salem, NC, USA Introduction Demographics Numerous pre-clinical animal models indicated TC-1734 (AZD3480) Patient disposition is given in Table 1 and baseline characteristics in Table 2. had a beneficial effect on cognition (1). Early work in man likewise Table 1 provided evidence TC-1734 (AZD3480) might have a beneficial effect Patient Disposition: Pre-screened= 373 Table 2: Baseline on cognition, especially attention and episodic memory (2). The Screened=224 Characteristics present study assessed the efficacy of TC-1734 (AZD3480) in an older TC- TC- population with subjective and objectively defined Age Associated Placebo Total Placebo TC-25mg TC-50 Memory Impairment (AAMI). 25mg 50mg Age 65.3 64.8 65.3 Methodology Randomized 66 59 68 193 (years) M:F 31:35 19:40 36:32 Completed 58 53 57 168 Volunteers aged 50-80 years with subjective memory impairment and WMS-R who scored at least 1 standard deviation below that seen in healthy Dropout AE 3 4 4 11 15.8 15.8 15.7 young adults on the Wechsler Memory Scale – Revised, Paired PAL Associate Learning Test, were randomized into a double blind fixed dose, placebo controlled, parallel group study. Subjects did not meet criteria for MCI. Treatment was for 16 weeks and subjects received 25 mg, 50 mg Table 3: Most Frequent Adverse Event by Treatment Group TC-1734 (AZD3480) or placebo. Routine safety measures were taken.
  • Hayward Et Al, 2017

    Hayward Et Al, 2017

    European Neuropsychopharmacology (]]]]) ], ]]]–]]] www.elsevier.com/locate/euroneuro Partial agonism at the α7 nicotinic acetylcholine receptor improves attention, impulsive action and vigilance in low attentive rats Andrew Haywardn, Lisa Adamson, Joanna C. Neilln Division of Pharmacy and Optometry, School of Health Sciences, University of Manchester, Manchester M13 9PT, UK Received 7 July 2016; received in revised form 9 January 2017; accepted 18 January 2017 KEYWORDS Abstract 5 choice-continuous Inattention is a disabling symptom in conditions such as schizophrenia and attention deficit/ performance task; hyperactivity disorder. Nicotine can improve attention and vigilance, but is unsuitable for clinical use 5C-CPT; due to abuse liability. Genetic knockout of the α7 nicotinic acetylcholine receptor (nAChR) induces α 7 nAChR; attention deficits therefore selective agonism may improve attention, without the abuse liability Animal Model; associated with nicotine. The α7 nAChR partial agonist encenicline (formerly EVP-6124) enhances Behavioural separa- memory in rodents and humans. Here we investigate, for the first time, efficacy of encenicline to tion; Low attentive improve attention and vigilance in animals behaviourally grouped for low attentive traits in the 5 choice-continuous performance task (5C-CPT). Female Lister Hooded rats were trained to perform the5C-CPTwithavariablestimulusduration(SD).Animalswerethengroupedbasedonperformance intoupperandlowerquartilesofd0 (vigilance) and accuracy (selective attention), producing high- attentive (HA) and low-attentive (LA) groups. LA animals showed an increase in selective attention and vigilance at 0.3 mg/kg encenicline, a reduction in impulsive action (probability of false alarms) and increase in vigilance following 1 mg/kg at 0.75 s SD. At 1 mg/kg, HA animals had reduced selective attention at 0.75 s SD and reduced vigilance at 0.75 and 1.25 s SD.
  • (Tert- Butoxycarbonyl)Amino](3 361442- 3

    (Tert- Butoxycarbonyl)Amino](3 361442- 3

    Alternative Name CAS 1. Product Name Use Number 320345- 2. Aclidinium bromide API 99-1 (2S)-[(tert- Butoxycarbonyl)amino](3 361442- 3. Saxagliptin int -hydroxyadamant-1- 00-4 yl)ethanoic acid 1,3- 1,3- 5001-18- 4. Dihydroxyadamantane Adamantanediol 3 1,3-Dimethyladamantane 702-79-4 memantine intermediate 5. 1-Acetylamido-3,5- 19982- 6. Memantine int dimethyladamantane 07-1 1- 7. 880-52-4 Acetylaminoadamantane 1- 4942-47- 8. 1-Adamantaneacetic acid Adamantylacetic 6 acid [2-(1- 6240-11- 9. 1-Adamantaneethanol Adamantylethano 5 l)] 1- 10. 1-Adamantanemethanol Adamantylmetha 770-71-8 nol 1- 1660-04- 1-Adamantyl methyl rimantadine intermediate; 11. Acetyladamantan 4 ketone e 1-Chloro-3,5- 707-36-8 memantine intermediate; 12. dimethyladamantane 1-Hydroxy-3,5- memantine intermediate; 13. 707-37-9 dimethyladamantane 2- 14. 2-Adamantanol Hydroxyadamant 700-57-2 ane 15. 2-Adamantanone 700-58-3 2-Aminoadamantane 10523- 16. hydrochloride 68-9 3-Amino-1-hydroxy- 3-Amino-1- 702-82-9 vildagliptin intermediate; 17. adamantane adamantanol 3- 38584- 18. (Hydroxymethyl)adamant 37-1 -1-ol 19. 3-aminomethyl- 865887- mequitazine intermediate; 20. quinuclidine 14-5 dihydrochloride zacopride intermediate; 6530-09- mezacopride intermediate; 3-Aminoquinuclidine 21. 2 pancopride intermediate; dihydrochloride azasetron intermediate; 3-Carbethoxy-dehydro- quifenadine intermediate; 50790- 22. quinuclidine sequifenadine intermediate; 85-7 hydrochloride quifenadine intermediate; 3- 6238-33- 23. sequifenadine intermediate; Carbethoxyquinuclidine 1 3-hydroxymethyl 79221- mequitazine intermediate; 24. quinuclidine 75-3 hydrochloride 3-Quinuclidine 6238-34- 25. carboxylic acid 2 hydrochloride 1619-34- penehyclidine intermediate; 26. 3-Quinuclidinol 7 clidinium intermediate; cevimeline intermediate; 3-Quinuclidinone 1193-65- 27.
  • WO 2016/001643 Al 7 January 2016 (07.01.2016) P O P C T

    WO 2016/001643 Al 7 January 2016 (07.01.2016) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/001643 Al 7 January 2016 (07.01.2016) P O P C T (51) International Patent Classification: (74) Agents: GILL JENNINGS & EVERY LLP et al; The A61P 25/28 (2006.01) A61K 31/194 (2006.01) Broadgate Tower, 20 Primrose Street, London EC2A 2ES A61P 25/16 (2006.01) A61K 31/205 (2006.01) (GB). A23L 1/30 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/GB20 15/05 1898 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (22) International Filing Date: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 29 June 2015 (29.06.2015) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (25) Filing Language: English KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (26) Publication Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (30) Priority Data: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 141 1570.3 30 June 2014 (30.06.2014) GB TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 1412414.3 11 July 2014 ( 11.07.2014) GB (84) Designated States (unless otherwise indicated, for every (71) Applicant: MITOCHONDRIAL SUBSTRATE INVEN¬ kind of regional protection available): ARIPO (BW, GH, TION LIMITED [GB/GB]; 39 Glasslyn Road, London GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, N8 8RJ (GB).
  • W O 2016/201373 A1 15 December 2016 (15.12.2016) W I PO I P C T

    W O 2016/201373 A1 15 December 2016 (15.12.2016) W I PO I P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2016/201373 A1 15 December 2016 (15.12.2016) W I PO I P C T (51) International Patent Classification: (74) Agents: QUEIROZ DE OLIVEIRA, Pierre et al.; Pepper A61K31/17(2006.01) A61P 25/00 (2006.01) Hamilton LLP, 500 Grant Street, Suite 5000, Pittsburgh, A61K 31/415 (2006.01) PA 15219-2507 (US). (21) International Application Number: (81) Designated States (unless otherwise indicated,for every PCT/US2016/037090 kind of national protection available): AE, AG, AL, AM, .) . AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) International Filng Date: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 10 June 2016 (10.06.2016) DO, DZ, EC, EE, EG, ES, Fl, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (26) Publication Language: English MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (30) Priority Data: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 62/174,983 12 June 2015 (12.06.2015) US SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 62/194,084 17 July 2015 (17.07.2015) US TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
  • The Α7 Nicotinic Agonist ABT-126 in the Treatment

    The Α7 Nicotinic Agonist ABT-126 in the Treatment

    Neuropsychopharmacology (2016) 41, 2893–2902 © 2016 American College of Neuropsychopharmacology. All rights reserved 0893-133X/16 www.neuropsychopharmacology.org The ɑ7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study ,1 1 1,2 1 George Haig* , Deli Wang , Ahmed A Othman and Jun Zhao 1 2 Abbvie Inc., North Chicago, IL, USA; Faculty of Pharmacy, Cairo University, Cairo, Egypt A double-blind, placebo-controlled, parallel-group, 24-week, multicenter trial was conducted to evaluate the efficacy and safety of 3 doses of ABT-126, an α7 nicotinic receptor agonist, for the treatment of cognitive impairment in nonsmoking subjects with schizophrenia. Clinically stable subjects were randomized in 2 stages: placebo, ABT-126 25 mg, 50 mg or 75 mg once daily (stage 1) and placebo or ABT-126 50 mg (stage 2). The primary analysis was the change from baseline to week 12 on the MATRICS Consensus Cognitive Battery (MCCB) neurocognitive composite score for ABT-126 50 mg vs placebo using a mixed-model for repeated-measures. A key secondary measure was the University of California Performance-based Assessment-Extended Range (UPSA-2ER). A total of 432 subjects were randomized and 80% (344/431) completed the study. No statistically significant differences were observed in either the change from baseline for the MCCB neurocognitive composite score (+2.66 [ ± 0.54] for ABT-126 50 mg vs +2.46 [ ± 0.56] for placebo at week 12; P40.05) or the UPSA-2ER. A trend for improvement was seen at week 24 on the 16-item Negative Symptom Assessment Scale total − ± − ± = score for ABT-126 50 mg (change from baseline 4.27 [0.58] vs 3.00 [0.60] for placebo; P 0.059).
  • Ion Channels

    Ion Channels

    UC Davis UC Davis Previously Published Works Title THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels. Permalink https://escholarship.org/uc/item/1442g5hg Journal British journal of pharmacology, 176 Suppl 1(S1) ISSN 0007-1188 Authors Alexander, Stephen PH Mathie, Alistair Peters, John A et al. Publication Date 2019-12-01 DOI 10.1111/bph.14749 License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology (2019) 176, S142–S228 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels Stephen PH Alexander1 , Alistair Mathie2 ,JohnAPeters3 , Emma L Veale2 , Jörg Striessnig4 , Eamonn Kelly5, Jane F Armstrong6 , Elena Faccenda6 ,SimonDHarding6 ,AdamJPawson6 , Joanna L Sharman6 , Christopher Southan6 , Jamie A Davies6 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 3Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 4Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, A-6020 Innsbruck, Austria 5School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 6Centre for Discovery Brain Science, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties.
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
  • Nicotinic Acetylcholine Receptors

    Nicotinic Acetylcholine Receptors

    nAChR Nicotinic acetylcholine receptors nAChRs (nicotinic acetylcholine receptors) are neuron receptor proteins that signal for muscular contraction upon a chemical stimulus. They are cholinergic receptors that form ligand-gated ion channels in the plasma membranes of certain neurons and on the presynaptic and postsynaptic sides of theneuromuscular junction. Nicotinic acetylcholine receptors are the best-studied of the ionotropic receptors. Like the other type of acetylcholine receptor-the muscarinic acetylcholine receptor (mAChR)-the nAChR is triggered by the binding of the neurotransmitter acetylcholine (ACh). Just as muscarinic receptors are named such because they are also activated by muscarine, nicotinic receptors can be opened not only by acetylcholine but also by nicotine —hence the name "nicotinic". www.MedChemExpress.com 1 nAChR Inhibitors & Modulators (+)-Sparteine (-)-(S)-B-973B Cat. No.: HY-W008350 Cat. No.: HY-114269 Bioactivity: (+)-Sparteine is a natural alkaloid acting as a ganglionic Bioactivity: (-)-(S)-B-973B is a potent allosteric agonist and positive blocking agent. (+)-Sparteine competitively blocks nicotinic allosteric modulator of α7 nAChR, with antinociceptive ACh receptor in the neurons. activity [1]. Purity: 98.0% Purity: 99.93% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in Water, Size: 10mM x 1mL in DMSO, 100 mg 5 mg, 10 mg, 50 mg, 100 mg (±)-Epibatidine A-867744 (CMI 545) Cat. No.: HY-101078 Cat. No.: HY-12149 Bioactivity: (±)-Epibatidine is a nicotinic agonist. (±)-Epibatidine is a Bioactivity: A-867744 is a positive allosteric modulator of α7 nAChRs (IC50 neuronal nAChR agonist. values are 0.98 and 1.12 μM for human and rat α7 receptor ACh-evoked currents respectively, in X.